PROQR THERAPEUTICS EO-,04/ NL0010872495 /
| 5/3/2024 8:01:35 AM | Chg. -0.0250 | Volume | Bid9:55:59 PM | Ask9:54:01 PM | High | Low |
|---|---|---|---|---|---|---|
| 1.8190EUR | -1.36% | 0 Turnover: 0.0000 |
-Bid Size: - | -Ask Size: - | 1.8190 | 1.8190 |
GlobeNewswire
4/23
ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held M...
GlobeNewswire
4/22
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
GlobeNewswire
2/15
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate f...
GlobeNewswire
1/19
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet ...
GlobeNewswire
1/5
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
GlobeNewswire
12/8/2023
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Oph...
GlobeNewswire
11/6/2023
ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing
GlobeNewswire
9/28/2023
ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference
GlobeNewswire
9/7/2023
ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment ...
GlobeNewswire
3/7/2022
ProQR Appoints John Maraganore, PhD, as Strategic Advisor to the Supervisory Board
GlobeNewswire
2/24/2022
ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial Results
GlobeNewswire
2/11/2022
ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LC...
GlobeNewswire
1/4/2022
ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarse...
GlobeNewswire
12/30/2021
ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos C...
